Voyager Therapeutics Inc
VYGR4.485USD
+0.225+5.28%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
248.63MMarket Cap
LossP/E TTM
More Details of Voyager Therapeutics Inc Company
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Company Info
Ticker SymbolVYGR
Company nameVoyager Therapeutics Inc
IPO dateNov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
Number of employees172
Security typeOrdinary Share
Fiscal year-endNov 11
Address75 Hayden Avenue
CityLEXINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02421
Phone18572595340
Websitehttps://www.voyagertherapeutics.com/
Ticker SymbolVYGR
IPO dateNov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.91K
-76.26%
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Todd Carter, Ph.D.
Dr. Todd Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.91K
-76.26%
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Neurocrine Biosciences Inc
15.46%
Armistice Capital LLC
8.65%
EcoR1 Capital, LLC
7.06%
BlackRock Institutional Trust Company, N.A.
6.91%
The Vanguard Group, Inc.
5.79%
Other
56.13%
Shareholders
Shareholders
Proportion
Neurocrine Biosciences Inc
15.46%
Armistice Capital LLC
8.65%
EcoR1 Capital, LLC
7.06%
BlackRock Institutional Trust Company, N.A.
6.91%
The Vanguard Group, Inc.
5.79%
Other
56.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
22.60%
Investment Advisor
20.89%
Corporation
15.46%
Hedge Fund
13.33%
Research Firm
2.30%
Individual Investor
1.28%
Bank and Trust
0.57%
Pension Fund
0.35%
Insurance Company
0.03%
Other
23.19%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
308
44.49M
80.20%
-3.76M
2025Q1
320
44.96M
81.54%
-6.59M
2024Q4
316
44.59M
81.64%
-6.62M
2024Q3
302
45.03M
82.56%
-8.55M
2024Q2
298
47.92M
88.05%
-2.79M
2024Q1
277
45.43M
90.18%
+7.85M
2023Q4
257
36.58M
85.81%
-1.09M
2023Q3
248
36.63M
86.15%
-1.09M
2023Q2
242
36.26M
85.84%
+5.02M
2023Q1
252
33.40M
79.73%
+1.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Neurocrine Biosciences Inc
8.58M
15.5%
--
--
Apr 07, 2025
Armistice Capital LLC
5.44M
9.82%
+40.00K
+0.74%
Mar 31, 2025
EcoR1 Capital, LLC
3.92M
7.08%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.64M
6.58%
+9.42K
+0.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
5.8%
-4.36K
-0.14%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.43M
2.58%
+56.45K
+4.12%
Mar 31, 2025
Vestal Point Capital, LP
1.25M
2.26%
+19.42K
+1.58%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.50M
2.7%
+115.67K
+8.38%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.10M
2%
+20.68K
+1.91%
Mar 31, 2025
Erste Asset Management GmbH
1.12M
2.02%
+58.41K
+5.52%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
